Ranbaxy Issues Drug Recall as It Preps for FDA Meeting

Last Updated Jul 10, 2009 4:25 PM EDT

Ranbaxy continued its mission to embarrass itself as much as possible by issuing a recall for a skin infection treatment just as it expects a final meeting with the FDA on the drugs the agency banned Ranbaxy from selling in the U.S., Bloomberg reported. The recalled drug is 40-milligram Sotret isotretinoin capsules. Ranbaxy told Bloomberg the recall was "normal." Normal for Ranbaxy, that's for sure, the company where nothing ever goes right. To review, in addition to this most recent recall: As BNET previously noted, the FDA has nonetheless continued to approve drugs from Ranbaxy. Normal, indeed.